New models for intranasal drug delivery
In this article, Dr Jon Volmer and Dr Jon Lenn discuss a new approach to formulation models to test drug delivery based on reconstituted nasal epithelium.
List view / Grid view
In this article, Dr Jon Volmer and Dr Jon Lenn discuss a new approach to formulation models to test drug delivery based on reconstituted nasal epithelium.
The polymerised form of oestrogen has shown success in mice at preventing further damage to the spinal cord after injury.
A synthetic cannabinoid has shown promise as a treatment for involuntary tremors by activating astrocytes in mouse models.
Researchers have found that the spasmolytic drug hymecromone can suppress astrocyte inflammatory responses, meaning it could be used to combat Alzheimer's disease.
Researchers have shown that a GLP-1/GIP dual-agonist targets the GIP receptor in the brain and CNS to reduce body weight and food intake.
Researchers have shown in cells and models that the central nervous system and neurons can become a target of SARS-CoV-2 infection.
Scientists who developed the E22W42 DC vaccine suggest it could be safer and more effective than previous anti-amyloid Alzheimer’s therapies.
New findings suggest that late-onset Alzheimer's Disease (AD) is driven by epigenetic changes in the brain.
Researchers have developed a molecule that can restore lost connections in the spinal cords and brains of mice with cerebellar ataxia, Alzheimer's disease and spinal cord injury.
Scientists have shown that a Selenium-based drug-molecule called ebselen and other novel compounds can delay ALS onset in mouse models.
Following an analysis of scientific literature, researchers say that COVID-19 may affect the entire nervous system, including the brain, spinal cord, nerves and muscles.
The novel technology allows researchers to create three-dimensional images of signal propagation and calcium concentration changes in the neocortex of live mice.
Drug Target Review explores five of the latest research developments in the field of spinal cord injury (SCI) repair.
A molecule has been shown to increase dopamine levels in the brains of mice, offering hope for stopping the progression of Parkinson’s.
A microRNA inhibitor has been identified which reduced the sizes of aggressive CNS tumours and improved survival in mice.